Cambridge Healthtech Institute’s 8th Annual

Next Generation Cell-Based Immunotherapies

Advances in CARs, TILs and TCRs

24-25 April 2024


Initial good responses to T cell therapies can be followed by rapid relapse owing to tumour-related mutations and evasion mechanisms put out by the tumour. Despite these challenges, these treatments are reaching the clinic and showing benefit to the patient, often when applied in combination or with co-stimulation. What learnings can we glean from the first-generation T cell therapies, and how can we apply them to next-generation CARs, TILs and TCRs? What new cell types and MOAs are being targeted? What new platforms, delivery systems, and engineering strategies are being developed? Which programs in the clinic show the most promise? We invite leading cell therapy companies and experts to join us to discuss these and many other questions at the Next Generation Cell-Based Immunotherapies conference, part of the 8th Annual Immuno-Oncology Summit Europe.


Coverage will include, but is not limited to:


  • Engineering CARs
    • In vivo Modification of T Cells
    • Logic Gates
    • Gene Editing Systems
    • Nanoparticle-based in vivo delivery
  • Novel CAR Approaches
    • Identifying and targeting suitable antigens on solid tumour cells
    • Improving CAR T cell Infiltration and persistance in the tumour microenvironment
    • Reducing risk of CAR T cell therapy-related toxicities
    • Next generation CAR T cell designs:
      • Armoured CARs, adapter and modular CARs, lateral CARs
    • CAR-NK, CAR-GDT, CAR-M, CAR-Neutrophils, CAR-CIK
    • Combination therapies with CPI, chemotherapies, cancer vaccines or oncolytic viruses
    • Allogeneic CAR-T Cell Therapies
      • Novel platforms and delivery systems
      • Clinical trials and preclinical development of allogeneic CAR T cell therapies
    • Advances in TCR-T and TCR-NK Cell Therapies
      • Targeting neoantigens
      • Overcoming immunosuppressive tumour microenvironment
      • Universal TCR-T cells
      • TCR-NK as next-generation T cell therapy
      • TCR-NK cells for combination therapies
    • Next-Generation TILs
      • TIL therapy for solid tumours
      • Improving the scalability and manufacturability of TIL products
      • TIL combination therapy


    The deadline for priority consideration is 6 October 2023.


    All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


    Opportunities for Participation:


    For more details on the conference, please contact:

    Mimi Langley

    Senior Conference Director

    Cambridge Healthtech Institute

    Phone: (+1) 781.972.5439



    For partnering and sponsorship information, please contact:

    Phillip Zakim-Yacouby

    Senior Business Development Manager

    Cambridge Healthtech Institute

    Phone: (+1) 781.247.1815


    Register Now